复发性早期妊娠丢失女性的母体抗甲状腺抗体与整倍体流产
该观察性队列研究纳入2004-2015年间两家学术医疗中心74例有复发性早期妊娠丢失史、甲状腺功能正常或亚临床甲状腺功能减退且完成母体抗甲状腺抗体检测的女性,共发生130次后续早期妊娠丢失。母体抗甲状腺抗体阳性率为17.6%,阳性组与阴性组整倍体流产频率无显著差异(42% vs. 56%)。作者认为该队列中检测或治疗可能并不必要。
要点
- 74例复发性早期妊娠丢失女性共发生130次后续早期妊娠丢失,抗甲状腺抗体阳性率17.6%。
- 抗甲状腺抗体阳性组与阴性组整倍体流产频率无显著差异(42% vs. 56%)。
- 作者认为该队列中检测或治疗可能并不必要。
核心结论
- 本研究未证明有复发性早期妊娠丢失史的女性中整倍体流产与母体抗甲状腺抗体存在关联。
- 作者认为因此该队列中检测或治疗可能并不必要。
研究设计与样本
- 观察性队列研究,设置于两家学术医疗中心。
- 纳入2004-2015年间有复发性早期妊娠丢失史、甲状腺功能正常或亚临床甲状腺功能减退、完成母体抗甲状腺抗体检测且至少发生一次后续早期妊娠丢失(<10周妊娠)的女性。
- 队列共74例受试者,随后发生130次早期妊娠丢失。
主要发现
- 队列中母体抗甲状腺抗体阳性率为17.6%。
- 抗甲状腺抗体阳性受试者的平均促甲状腺激素显著更高。
- 其余人口学特征未见显著差异。
- 抗甲状腺抗体阳性组与阴性组的早期妊娠丢失类型比较:阳性组流产70%、未显示妊娠丢失30%,阴性组流产55%、未显示妊娠丢失43%,阳性组呈现流产多于未显示妊娠丢失的趋势。
- 抗甲状腺抗体阳性组与阴性组整倍体流产频率无显著差异(42% vs. 56%)。
关键数值与推荐
- 后续流产通过常规细胞遗传学分析评估,并在有指征时进行微卫星分析和/或比较基因组杂交/单核苷酸多态性检测。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether an association exists between maternal antithyroid antibodies and euploid miscarriage in women with recurrent early pregnancy loss (REPL). DESIGN: Observational cohort study. SETTING: Two academic medical centers. PATIENT(S): Women seen between 2004-2015 with a history of REPL, who were euthyroid or had subclinical hypothyroidism, had maternal antithyroid antibody testing and had at least one subsequent early pregnancy loss (<10 weeks' gestation). INTERVENTION(S): Thyroid function and antibodies were measured at consultation. Subsequent miscarriages were assessed by conventional cytogenetic analysis, and when indicated, microsatellite analysis and/or comparative genomic hybridization/single nucleotide polymorphisms were performed. MAIN OUTCOME MEASURE(S): Determine whether maternal antithyroid antibodies are associated with euploid miscarriage. RESULT(S): Cohort consisted of 74 subjects with REPL who had 130 subsequent early pregnancy losses. The prevalence of maternal antithyroid antibodies in the cohort was 17.6%. Mean TSH was significantly higher among subjects with maternal antithyroid antibodies. Otherwise, no significant differences in demographics were noted. When comparing types of early pregnancy losses between the two groups, a trend toward having more miscarriages than nonvisualized pregnancy losses was noted among subjects with maternal antithyroid antibodies (70% and 30%) compared with subjects without maternal antithyroid antibodies (55% and 43%). No significant difference was noted in the frequency of euploid miscarriage between subjects with and without maternal antithyroid antibodies (42% vs. 56%). CONCLUSION(S): Our study did not demonstrate an association between euploid miscarriage and maternal antithyroid antibodies in subjects with a history of REPL. Therefore, testing or treatment in this cohort may not be warranted.
引用
- Cueva S, Burks C, McQueen D, et al. Maternal antithyroid antibodies and euploid miscarriage in women with recurrent early pregnancy loss. Fertil Steril. 2018. PMID: 30098697. doi:10.1016/j.fertnstert.2018.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。